Literature DB >> 2546468

Evidence of PAF-acether metabolic pathway activation in antigen challenge of upper respiratory airways.

A Miadonna1, A Tedeschi, B Arnoux, A Sala, C Zanussi, J Benveniste.   

Abstract

Lyso-PAF-acether and PAF-acether (formerly platelet-activating factor) were detected in nasal secretions from patients with hay fever who underwent local antigen challenge. Lyso-PAF release was observed in 12 of 13 patients, with a maximum (p less than 0.001) 5 min after stimulation and a progressive decrease during the first hour. PAF was detected in the 5-min postchallenge nasal washings from two of 13 subjects. After HPLC, this mediator was found in four of seven postchallenge nasal washings submitted to this procedure, with a peak 5 min and 10 min after provocation. Histamine analysis revealed a significant (p less than 0.001) but time-limited (5 min) release in nasal secretion. The pattern of immunoreactive leukotriene C4 showed a maximal peak (p less than 0.01) 5 min after allergen provocation, with raised levels for 20 min. Nasal stimulation with nebulized saline solution or grass pollens in healthy subjects and in patients suffering from allergic rhinitis caused by Dermatophagoides pteronyssinus was followed by no local mediator release. These data indicate that, in addition to histamine and peptide-leukotrienes, lyso-PAF and PAF are released in nasal secretions after local antigen stimulation in patients with hay fever, with a preponderance of lyso-PAF response. On the basis of these results, it is conceivable that these ether-phospholipids may be involved in allergic inflammation of human nasal airways.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2546468     DOI: 10.1164/ajrccm/140.1.142

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  7 in total

1.  Therapeutic effects of intranasal tocotrienol-rich fraction on rhinitis symptoms in platelet-activating factor induced allergic rhinitis.

Authors:  Cheryl Wei Ling Teo; Stephanie Jia Ying Png; Yee Wei Ung; Wei Ney Yap
Journal:  Allergy Asthma Clin Immunol       Date:  2022-06-13       Impact factor: 3.373

2.  Rupatadine: pharmacological profile and its use in the treatment of allergic rhinitis.

Authors:  M Sudhakara Rao; D Dwarakanatha Reddy; P S N Murthy
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2010-01-09

3.  Modulation of allergen-induced nasal symptoms and mediator release by treatment with N-acetyl-aspartyl-glutamate (ZY15106).

Authors:  A Miadonna; M Cottini; C Candiani; A Tedeschi
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

4.  Platelet activating factor induced respiratory mucosal damage.

Authors:  K Hisamatsu; T Ganbo; T Nakazawa; Y Murakami
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

Review 5.  Role of histamine and platelet-activating factor in allergic rhinitis.

Authors:  V Alfaro
Journal:  J Physiol Biochem       Date:  2004-06       Impact factor: 5.080

Review 6.  Hyperresponsiveness in the human nasal airway: new targets for the treatment of allergic airway disease.

Authors:  P J Turner; J C Foreman
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

7.  Evaluation of nasal symptoms induced by platelet activating factor, after nasal challenge in both healthy and allergic rhinitis subjects pretreated with rupatadine, levocetirizine or placebo in a cross-over study design.

Authors:  Joaquim Mullol; Cesar Picado; Rosa Muñoz-Cano; Antonio Valero; Ignacio Izquierdo; Jaume Sánchez-López; Alejandro Doménech; Joan Bartra
Journal:  Allergy Asthma Clin Immunol       Date:  2013-11-01       Impact factor: 3.406

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.